重组抗小鼠VEGFR-2单抗(DC101) | Syd Labs PA007527.r1
体内实验级重组抗小鼠VEGFR-2单抗(DC101)，大鼠IgG1 Kappa是用哺乳动物细胞生产的重组抗体，纯度>95%，适用于体内和体外研究，比如体内阻断 VEGF/VEGFR-2 信号通路。Syd Labs PA007527.r1抗小鼠VEGFR-2抗体不变区为大鼠Rat IgG1 Kappa (rIgG1或r1)，可与重组大鼠IgG1同型对照抗体配套使用。样品制备条件和样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007527.r1 |
|---|---|
| 产品名称 | 重组抗小鼠VEGFR-2单抗(DC101) | Syd Labs PA007527.r1 |
| 英文名 | In Vivo Grade Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Rat IgG1 Kappa |
| 说明书 | 抗小鼠VEGFR-2抗体说明书 |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | CD309, FLK1, VEGFR, KDR, VGFR2, VGR2, 激酶插入结构域受体（KDR）, 胎肝激酶‑1（Flk‑1） |
| 概述 | 体内实验级重组抗小鼠VEGFR-2单抗(DC101) ，大鼠IgG1 Kappa是用哺乳动物细胞生产的重组抗体 |
| 克隆号 | DC101 |
| 同种型 | 大鼠 IgG1, kappa |
| 特异性 | VEGFR-2 |
| 应用 | 蛋白印迹法（Western blot）、免疫共沉淀（IP）、流式细胞术（FC），以及各种体外和体内功能分析，比如动物体内实验。 |
| 抗体形式 | 0.2 μM过滤溶液，1x PBS |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠VEGFR-2单抗(DC101) ，大鼠IgG1 Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存1个月。 如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007527.r1 Syd Labs 重组抗小鼠VEGFR-2 / Flk-1 / CD309单抗(DC101) 用哺乳动物细胞生产，可与重组大鼠IgG1同型对照抗体配套使用。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | 蛋白印迹法（Western blot）、免疫共沉淀（IP）、流式细胞术（FC），以及各种体外和体内功能分析，比如动物体内实验。 |
文献
PA007527.r1: Syd Labs体内实验级重组抗小鼠VEGFR-2单克隆抗体（克隆号DC101），大鼠IgG1 Kappa（In Vivo Grade Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Rat IgG1 Kappa）
抗小鼠 VEGFR-2 单抗（克隆号：DC101，大鼠 IgG1 来源）是一种专门靶向小鼠血管内皮生长因子受体-2（VEGFR-2/Flk-1/CD309）的阻断性抗体。DC101 能有效结合 VEGFR-2 胞外域，竞争性阻断配体 VEGF 的结合及其下游信号通路的激活，从而显著抑制肿瘤血管生成及内皮细胞增殖。在肿瘤学及血管生物学研究中，抗小鼠 VEGFR-2 单抗（DC101）是评估抗血管生成疗法、调控肿瘤微环境以及探索联合免疫治疗机制的标准工具抗体。
我们的重组 VEGFR-2 抗体包含大鼠抗小鼠 VEGFR-2 单克隆抗体（杂交瘤克隆名称或编号：DC101）的部分（可变区）或完整氨基酸序列。
抗小鼠VEGFR-2单抗（DC101）部分参考文献:
1. Distinct functions of epidermal and myeloid-derived VEGF-A in skin tumorigenesis mediated by HPV8.
Ding, X., et al. Cancer Res. 2015 Jan 15;75(2):330-43. doi: 10.1158/0008-5472.CAN-13-3007. PMID: 25414138
“VEGF mediates its activities primarily through binding to two receptor tyrosine kinases, known as VEGFR1 and VEGFR2, as well as to coreceptors including neuropilins. …Inhibition of VEGFR2 was performed by intraperitoneal injections of anti-VEGFR2 blocking antibody (DC101, BioXcell) or the corresponding isotype-matched control antibody (IgG1, BioXcell; 40 mg/kg body weight in PBS). …This antibody has been shown to be a potent inhibitor of VEGFR2. …To investigate whether the vasculature is a target of VEGF in HPV8-mediated skin tumor development, we used an antibody-based strategy to inhibit angiogenesis by blocking VEGFR2 signaling in endothelial cells. …For this purpose at days 10 and 34 after UV exposure, the epidermis was separated from dermis and epidermal expression for VEGF, VEGFR2, VEGFR1, and Nrp1 was determined by qRT-PCR analysis.”
Kizhatil, K., et al. PLoS Biol. 2014 Jul;12(7):e1001912. doi: 10.1371/journal.pbio.1001912. PMID: 25051267
“Functional inhibition of KDR (VEGFR2), a critical receptor in initiating angiogenesis, shows that this receptor is required during canalogenesis. …FLT4 (VEGFR3) is another key protein required for lymphatic development and also serves as a marker for lymphatics. …To begin to define the molecules necessary for SC development, we tested the functional importance of the tyrosine kinase receptor KDR (alias VEGFR2, a receptor for vascular endothelial growth factor, or VEGF). …This is consistent with a recent report that mice heterozygous for mutations in both Kdr and Flt1 (Vegfr1) have elevated IOP. …The DC101- and control-injected eyes have a similar LVP. Note that there is substantial regional variation in LVP architecture in every eye.”
Chatterjee, S., et al. PLoS One. 2013 May 8;8(5):e63674. doi: 10.1371/journal.pone.0063674. PMID: 23667656
“VEGF-A signals by binding to its receptors VEGFR-1 (FLT-1) and VEGFR-2 and is known to also promote inflammation and epithelial to mesenchymal transition. …VEGF-A signaling through its receptors FLT-1 and VEGFR-2 also regulates TGF-β expression that in turn regulates corneal wound healing. …This upregulation of VEGF-A was found to be functionally relevant since treatment of Jam-A deficient mice with a function blocking VEGFR-2 antibody resulted in a partial rescue of the observed wound-healing defect. …Further, the mRNA levels of FLT1 (VEGFR-1) or VEGFR-2 appeared to be slightly increased in Jam-Agt/gt compared to WT mice although these differences were not statistically significant. …The above results show that JAM-A negatively regulates wound-induced inflammation, angiogenesis and scarring by modulating the VEGF-A/VEGFR-2 pathway.”